A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model

INTRODUCTION: Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4(+) T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuang, Yu, Yang, Geng, Shuang, Wang, Dongmei, Zhang, Li, Xie, Xiaoping, Wu, Bing, Li, Chaofan, Xu, Hanqian, Li, Xiaolin, Hu, Yanxin, Zhang, Lianfeng, Kaether, Christoph, Wang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075150/
https://www.ncbi.nlm.nih.gov/pubmed/24987466
http://dx.doi.org/10.1186/alzrt256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075150/
https://www.ncbi.nlm.nih.gov/pubmed/24987466
http://dx.doi.org/10.1186/alzrt256

Ejemplares similares